Wyeth Extends Agreement with Affymetrix to 15 Years

26-Oct-2006

Affymetrix Inc. announced that Wyeth has signed another agreement with Affymetrix to use GeneChip(R) microarray technology for three more years, further extending the relationship that began in 1994. Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process. The company will continue to use Affymetrix microarray technology to identify new drug targets and gain a better understanding of the genetic markers that potentially correlate with a patient's response to therapy.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances